微电生理(688351) - 2023 Q1 - 季度财报

Financial Performance - The company reported a net profit of RMB 5,982,111.56 for the first quarter of 2023, primarily driven by non-operating income[6]. - The company reported a net loss of ¥9,326,097.49, compared to a net loss of ¥161,475.33 in the previous period, indicating a significant decline in profitability[15]. - The total operating profit was reported at -¥7,326,097.95, a substantial drop from -¥191,475.92 in the prior period[14]. - The total comprehensive loss for the period was ¥9,326,097.49, compared to a loss of ¥161,475.33 in the prior period[15]. - The net profit attributable to shareholders for Q1 2023 was -9,326,097.49 RMB, which is not applicable for comparison[45]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to RMB 1,794,906,439.62, showing a slight increase from RMB 1,788,331,481.27 at the end of 2022[11]. - The total current assets were reported at RMB 1,576,429,271.06, a slight decrease from RMB 1,595,986,425.47 in the previous year[11]. - The company's non-current assets increased to RMB 218,477,168.56 from RMB 192,345,055.80, reflecting a growth of about 13.6%[12]. - The total liabilities of the company as of March 31, 2023, were RMB 78,469,354.86, up from RMB 66,175,646.65, indicating an increase of approximately 18%[12]. - The total liabilities increased to ¥127,116,405.64 from ¥112,837,617.35, showing a growth of 12.6%[21]. - The company's capital reserve increased to ¥1,261,626,105.15 from ¥1,260,003,837.60, reflecting a slight growth of 0.1%[21]. Cash Flow - The company's cash and cash equivalents decreased to RMB 309,988,692.79 from RMB 584,887,873.89 in December 2022, representing a decline of approximately 47%[11]. - The cash inflow from operating activities in Q1 2023 was 72,661,826.96 RMB, compared to 65,483,818.29 RMB in Q1 2022[25]. - The cash outflow from operating activities was 86,449,337.51 RMB, up from 66,284,803.95 RMB in the same period last year[25]. - The company experienced a net cash outflow from investing activities of -¥258,807,625.67, compared to -¥2,879,395.77 in the previous period[17]. - The cash and cash equivalents at the end of the period were ¥302,819,817.79, down from ¥421,807,934.72, indicating a decrease of 28.1%[17]. Revenue and Expenses - The total revenue for Q1 2023 was 52,132,729.40 RMB, representing a decrease of 6.33% year-over-year[45]. - The total operating revenue for Q1 2023 was RMB 52,132,729.40, a decrease from RMB 55,658,087.32 in Q1 2022, representing a decline of approximately 9.1%[57]. - The total operating costs increased to RMB 66,593,648.07 in Q1 2023 from RMB 55,666,530.31 in Q1 2022, indicating a rise of about 19.6%[57]. - Research and development expenses increased to ¥23,452,627.63, up from ¥16,688,365.10, reflecting a 40.5% year-over-year growth[14]. - Research and development expenses totaled 27,001,815.48 RMB, accounting for 51.79% of operating revenue, an increase of 16.03 percentage points from the previous year[29]. - Sales expenses rose to ¥19,950,225.23, compared to ¥15,525,943.11, marking a 28.5% increase[14]. Market Strategy - The company is focusing on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[4].